Leptomeningeal disease (LMD) involves the spread of malignant
|
|
- Hester Megan Stevenson
- 5 years ago
- Views:
Transcription
1 1311 Pretreatment Cognitive Performance Predicts Survival in Patients with Leptomeningeal Disease Audrey M. Sherman, Ph.D. 2 Kurt Jaeckle, M.D. 1 Christina A. Meyers, Ph.D. 2 1 Department of Neurology, Mayo Clinic, Jacksonville, Florida. 2 Department of Neuro-Oncology, M. D. Anderson Cancer Center, Houston, Texas. BACKGROUND. Leptomeningeal disease (LMD) involves the spread of malignant cells from solid tumors to the cerebrospinal fluid or to the leptomeninges. LMD has a very poor prognosis and it is difficult to diagnose and follow with traditional diagnostic tools. The purposes of this study were to characterize cognitive functioning of LMD patients before treatment and to determine if measurement of cognitive functioning could be used to predict survival time. METHODS. Thirty-seven subjects with LMD were administered the Mattis Dementia Rating Scale (DRS) before they received treatment and statistical analyses were performed. RESULTS. The Conceptualization subtest of the DRS was the most sensitive to disease course. It was the only individual subtest to predict survival and it was the most impaired subtest across individual subjects. These results support earlier findings of a frontal-subcortical pattern of dysfunction in LMD patients. Cognitive performance at time of LMD diagnosis predicts survival time. Age and clinical status, two factors often correlated with survival in the cancer literature, did not predict survival time for our LMD population. In addition, there were no correlations between survival time and previous medical history or demographic factors. CONCLUSIONS. Neuropsychological assessment appears to be a valuable tool both for tracking disease course over time and for predicting survival of patients. Cancer 2002;95: American Cancer Society. DOI /cncr KEYWORDS: leptomeningeal disease, neuropsychology, cognitive patterns, interleukin-2. Presented in poster session at the International Neuropsychology Society Meeting, Denver, CO, February 9 12, Address for reprints: Christina A. Meyers, Ph.D., Department of Neuro-Oncology, P.O. Box 431, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030; Fax: ; cameyers@mail.mdanderson.org Received January 3, 2002; revision received March 21, 2002; accepted April 16, Leptomeningeal disease (LMD) involves the spread of malignant cells from solid tumors to the cerebrospinal fluid (CSF) or to the leptomeninges (pia mater and the arachnoid), which are tissues that envelop the brain and spinal cord. It is a relatively rare process, occurring in approximately 5% of cancer patients. 1 However, it is believed that its incidence will increase as survival time for patients with systemic cancers increases. This disease has a very poor prognosis, with estimates of only 20% response to treatment and a median survival time of only 4 months. 2 Patients with LMD exhibit a wide variation in clinical presentation, as the disease affects all aspects of the central nervous system, including the cerebral hemispheres, the cranial nerves, and the spinal cord. Symptoms may include headache, mental status change, nausea, hemiparesis, papilledema, diplopia, difficulty with vision or hearing, gait instability, and seizures. 1 Because many of these symptoms are nonspecific, LMD can be particularly difficult to diagnose and follow clinically. It is diagnosed often with a combination of CSF cytology and radiographic data. However, these methods have proven problematic, as results are 2002 American Cancer Society
2 1312 CANCER September 15, 2002 / Volume 95 / Number 6 often nonspecific and inconclusive. CSF studies may show abnormalities in intracranial pressure, cell count, and glucose and protein levels, all of which are nonspecific findings. Often, the CSF yields positive cytology for LMD, but this is not always the case, and there is controversy concerning appropriate cutoff criteria for positive versus negative classification. Although neuroimaging is often used to support an LMD diagnosis, there is a high rate of false-negative results for both computed tomographic (CT; 58%) and magnetic resonance imaging (MRI; 30%) scans. 1 Therefore, it is important to find ways to better pinpoint and classify the clinical status of patients with LMD. This is particularly vital for tracking disease progression during clinical trials for treatment protocols, as the traditional methods of CSF analysis and radiographic information may not be sensitive or specific enough to provide clear data points. One marker of clinical status and disease progression that has been relatively unexplored is cognitive status. Cognitive assessment can be a relatively time-efficient and cost-effective procedure. Several recent studies have described the cognitive effects of various protocols on patients with LMD. 3 6 However, there have been very few clear descriptions of cognitive effects for patient populations with LMD before treatment. The purpose of the current study is to describe and characterize the cognitive functioning of a relatively large group of patients with recently diagnosed LMD before they received treatment. This will establish a baseline from which cognitive changes resulting from treatment can be examined in future research. In addition, this study examines the correlation between cognitive functioning at baseline and survival time. It is predicted that patients exhibiting higher degrees of impairment at baseline neuropsychological testing will also have a shorter time of survival after LMD diagnosis. MATERIALS AND METHODS Subjects Patients were diagnosed with leptomeningeal carcinoma secondary to melanoma, breast carcinoma, lung carcinoma, or other solid tumors resulting from systemic cancer. LMD diagnosis was defined as a positive CSF cytology for malignant cells or radiographic evidence of CSF disseminated tumor on CT or MRI scans. All patients received treatment at the M. D. Anderson Cancer Center (Houston, TX) and were included in the subject pool if they were able to undergo a baseline neuropsychological examination before they received any therapy. Baseline neuropsychological assessment occurred within several days of the LMD diagnosis and before the patients received any treatment. For the purposes of this study, the date of Ommaya shunt placement was considered the date of LMD diagnosis. Data collection began in 1990 and continued through Informed consent was obtained from each patient. The population for the current study consisted of 37 patients who had been diagnosed with LMD and received baseline neuropsychological assessments. Following baseline assessment, subjects were enrolled in one of two protocols, or they did not receive treatment. Twenty subjects received treatment with intraventricular interleukin-2 (IL-2) and seven subjects received chemotherapy treatment with cytosine arabinoside (ara-c). Ten subjects did not receive any treatment. Of the 37 subjects, 21 had a primary diagnosis of melanoma, 11 of breast carcinoma, 4 of lung adenocarcinoma, and 1 of glioblastoma multiforme. There were 25 females and 12 males. The mean age of all subjects was 43.9 (standard deviation [SD] 9.7) years and the mean level of education was 14.2 (SD 2.8) years. Neuropsychological Measure Patients were administered the Dementia Rating Scale (DRS). 7 The DRS was selected because it can be administered quickly (usually between 15 minutes and 1 hour) and easily at a patient s bedside, as only a test booklet, pencil, and paper are required. In addition, the DRS is well validated and normed and it assesses five general areas of cognition: attention (Attention subtest), frontal lobe executive functions (Initiation subtest), reasoning (Conceptualization subtest), visual-construction skills (Construction subtest), and short-term memory (Memory subtest). It was designed to track dementia in elderly patients and is, therefore, an easy examination for younger, healthier subjects to perform without error. Normal elderly subjects generally obtain 97% correct or higher (scoring points out of a possible 144). Therefore, any scores below 95% are considered below expectation, particularly for younger subjects. The DRS was designed to provide an overall score (out of 144 points), as well as scores for each of the five general cognitive domains. However, it is difficult to draw specific conclusions about subtest scores in terms of brain functioning due to the fact that each subtest of the DRS contains multiple individual items that assess different cognitive functions. Hoffer et al. 8 investigated the DRS by performing a statistical factor analysis on DRS items and found that although the analysis yielded clusters generally similar to the subtest clusters, some items that are grouped together in subtests may not be assessing similar cognitive functions. Therefore, group performance on individual items was examined. Following the example of several stud-
3 Cognitive Function in LMD Patients/Sherman et al TABLE 1 Influence of Previous Treatment/Complications on Baseline Total DRS Scores Subject group comparison Previous Treatment Previous chemotherapy (n 26) vs. none (n 11) 0.32 Previous immunotherapy (n 14) vs. none (n 23) 0.65 Both chemotherapy/immunotherapy (n 11) vs. others (n 26) 0.84 Neither chemotherapy/immunotherapy (n 8) vs. others (n 29) 0.74 Brain metastases (n 20) vs. none (n 17) 0.77 If brain metastases (n 20): Radiation therapy (n 13) vs. no radiation therapy (n 7) 0.81 Surgery (n 12) vs. no surgery (n 8) 0.18 Single metastasis (n 7) vs. multiple metastases (n 13) 0.67 Right vs. left hemisphere 0.16 Primary diagnosis Melanoma (n 21) vs. breast carcinoma (n 11) 0.37 Melanoma (n 21) vs. all other diagnoses (n 16) 0.59 Significance (two-tailed) TABLE 2 Survival Time (Weeks) Groups No. Mean (SD) Median (SEM) All subjects (9.35) 15.0 (3.5) Interleukin-2 group (12.3) 18.0 (4.1) Chemotherapy group (6.6) 10.0 (4.0) ies that used the DRS to examine patterns of cognitive dysfunction, 9 11 the method of examining percentage correct of responses within individual items was utilized to compare performance across items that contained different point values and different numbers of exemplars. Individual items included repetition of digits forward, repetition of digits backward, the ability to follow one and two-step commands, word fluency for a semantic category (supermarket items), word fluency for a semantic category with visual cues (name things examiner is holding or wearing), verbal repetition of nonsense syllables, motor programming, visuospatial construction (copy) of alternating figures, visuospatial construction (copy) of geometric designs, abstract visual reasoning (similarities of shapes), abstract verbal reasoning (similarities between verbally presented items), orientation, visual attention and discrimination of target stimuli, visual recognition memory for words and designs, and recall of sentences that were read or composed recently. RESULTS Effects of Previous Treatment and Complications Because many subjects had experienced long and complex medical problems and treatments before receiving their LMD diagnosis and entering our study, other factors that might affect cognitive functioning were investigated. As the data were distributed parametrically, two-tailed t tests were used to compare group cognitive performance at baseline according to these various factors. A conservative P level was used to correct for multiple comparisons (P 0.01; Table FIGURE 1. Survival curve of subjects with leptomeningeal disease (n 37). 1). Previous treatment and medical complications did not significantly influence neuropsychological performance at baseline. To ensure that subjects did not differ significantly according to the treatment protocol they received (IL-2 vs. ara-c), treatment groups were compared. They did not differ significantly on baseline cognitive results (P 0.25). Implications for Survival Time Of the 37 subjects, 32 had died in the time interval between baseline neuropsychological assessment and data analysis (August 1998). The Kaplan Meier procedure was used to statistically account for and censor survivors from further analysis. Table 2 shows the survival time and Figure 1 shows a survival curve. Baseline assessment occurred within several days of the subjects receiving the LMD diagnosis. For the entire subject group, the mean survival time from baseline assessment to date of death was 36.6 weeks (SD 9.35). The median survival time from baseline testing was 15.0 weeks (standard error of the mena [SEM] 3.5). The the age of the subjects did not influence their survival time (Spearman correlation coefficient 0.183, two-tailed significance 0.28). To determine if general clinical status at baseline was related to survival time, a correlation was performed between survival time and rating on the Karnofsky performance scale (KPS). It should be noted that there is no
4 1314 CANCER September 15, 2002 / Volume 95 / Number 6 TABLE 3 Correlation of DRS Scores and Survival Time Subtests Spearman correlation coefficient Significance (one-tailed) Conceptualization Initiation Memory Construction Attention Total DRS score TABLE 4 DRS Subtest Scores Subtests Percentage correct No. subjects impaired Attention /37 Construction /37 Initiation /37 Memory /37 Conceptualization /37 Total DRS score /37 direct reflection of cognitive functioning in this scale. The correlation between KPS status and survival time was not significant (P 0.17), likely due to the restricted range of KPS scores ( 70). We investigated whether there was a correlation between cognitive performance at baseline and ultimate survival time, the results of which are reported in Table 3. At baseline, total DRS scores across the subject population correlated significantly with survival time past baseline (Spearman correlation 0.46, onetailed significance ) and higher scores at baseline correlated positively with a longer survival time. This finding remained completely consistent whether or not the five surviving subjects were statistically censored or included in the correlation. This finding is particularly striking given the fact that survival did not correlate with factors that would be expected to influence survival time, such as age and general clinical status (KPS rating). To determine whether performance on particular subtests of the DRS correlated with survival time, correlations between each subtest and survival time were computed. Only the Conceptualization subtest score correlated significantly with survival time (Spearman correlation 0.42, one-tailed significance 0.008), with higher scores correlating to longer time of survival from baseline. Scores on the Initiation subtest approached a significant correlation with survival time (Spearman correlation 0.40, one-tailed significance 0.011). However, other subtest scores (Memory, Construction, Attention) did not correlate significantly with survival time. In additional analyses, the group receiving IL-2 (n 20) was compared with the group receiving chemotherapy (n 7). There was a notable difference in survival time between the groups. The IL-2 group survived longer, with a mean survival time of 42.3 weeks (SD 12.3) and a median of 18.0 weeks (SEM 4.1), whereas the group receiving chemotherapy survived for a mean of 20.5 weeks (SD 6.6) and a median of 10.0 weeks (SEM 4.0). However, the difference between the two groups was not statistically significant due to the low statistical power resulting from too few subjects in the chemotherapy group. It is noteworthy that the total group receiving either chemotherapy or IL-2 treatment (n 27) survived longer (mean 34.6 weeks, SD 48.6) than the group receiving no treatment (n 10; mean 16.4 weeks, SD 10.3), although this result was not statistically significant (one-tailed significance 0.04). However, there were no statistical differences in survival time between each treatment group individually and the no-treatment group, or when all three groups were compared in an analysis of variance analysis, likely due to low statistical power. Pattern of Cognitive Impairment Baseline scores on the DRS were examined for the entire subject population. The percentage of items correct for all possible items was calculated for each subject and averaged across subjects (Table 4). The average percentage correct for total DRS score was 91.2%. This finding is below the expected performance level of normal subjects (95% or greater). On subtests, the highest average percentage correct was obtained for Attention (96.6%) followed by Construction (93.7%), Initiation (89.5%), Conceptualization (89.0%), and Memory (89.0%). To examine further the range of impairment suggested by these scores, z-scores were calculated for the total score and subtest scores according to the normative data published in the DRS manual, which were based on a sample of patients between the ages of 65 and 81 years (Table 4). Subjects whose scores were more than 1.5 SDs below the mean of the normative sample were considered to be impaired. Using this criterion, 10 of the 37 subjects were within the impaired range for total DRS score. On subtest scores, the fewest subjects fell within the impaired range on Attention (3 of 37) followed by Construction (4 of 37), Memory (5 of 37), Initiation (9 of 37), and Conceptualization (10 of 37). Further data analysis revealed that these 10 impaired subjects did not differ from the rest of the subject population according to variables of
5 Cognitive Function in LMD Patients/Sherman et al TABLE 5 DRS Individual Items Item Digits Backward 78.4 Sentence Recall 83.4 Supermarket Fluency 84.3 Verbal Conceptualization 87.0 Orientation 87.1 Alternating Movements 91.9 Visual Conceptualization 91.9 Verbal Repetition 93.2 Alternating Designs (copy) 93.2 Word Recognition 95.1 Counting As 96.8 Design recognition 98.0 Visual Fluency 99.0 Follow Commands 99.2 Digits Forward 100 Read Words 100 Match Designs 100 Percentage correct (mean) demographics, previous medical history, or previoustreatment (P 0.15 for all two-tailed t tests). When individual items were examined, again using the percentage correct technique, the lowest scores were obtained on the following items: Digits Backward (78.4%), Sentence Recall (83.4%), Supermarket Fluency (84.3%), Verbal Conceptualization (87.0%), and Orientation (87.1%). Table 5 contains the average percentage correct for each item. DISCUSSION The current study yielded several interesting findings. The most noteworthy finding is that baseline cognitive performance (at the time of LMD diagnosis and before treatment) correlated positively and significantly with the length of survival time. Surprisingly, baseline cognitive performance was the only variable that predicted survival. Age and clinical status (KPS rating) at baseline did not correlate significantly with survival, although these variables predicted prognosis and survival time among high-grade malignant glioma patients. 12 Previous medical history or treatment variables did not influence cognitive performance at baseline assessment. In particular, radiation therapy to the brain can cause a similar pattern of cognitive impairments. However, patients who received whole brain radiation therapy for brain metastases did not perform differently from those who did not receive radiation treatment. No patient received radiation therapy for bulky LMD. Our data suggest that assessment of cognitive function may be helpful in tracking the disease course. This is of particular importance because commonly used surrogate endpoints of LMD progression such as MRI and cytology can be unreliable or variable among patients or between assessments. Of the DRS subtest scores, only the Conceptualization subtest score (which assesses reasoning ability) correlated significantly with the length of survival time, suggesting that performance on this subtest may be especially sensitive to disease course and may hold possible implications for survival. Usually, conceptualization and other frontal lobe functions are not assessed in brief screening mental status examinations, such as the Mini-Mental Status Examination (MMSE). 13 Meyers et al. 14 found that the MMSE can be insensitive to cognitive changes in mental functioning in clinical trials of neurotoxic cancer drugs, as it was designed as a screening tool for dementia rather than to track more subtle cognitive changes. Conversely, The DRS assesses a wide range of cognitive domains, including frontal lobe functioning, in a relatively short amount of time. We also investigated the pattern of neuropsychological performance of newly diagnosed LMD patients before they received treatment. In the only previous study that investigated and described specific cognitive effects of LMD before treatment, 15 Siegel et al. examined 26 patients with recently diagnosed LMD using neuropsychological assessment, CT scan, and measurement of regional cerebral blood flow. Only 15 patients were able to undergo the neuropsychological testing. Of these, the investigators found that 93% of their patient population exhibited low performance on neuropsychological tests compared with a control group. Specifically, impairments were noted in the domains of attention, recent memory, and abstraction. As predicted, our subject group demonstrated a similar pattern of cognitive impairment. Among the five subtests of the DRS, our group performed worse on the Conceptualization, Memory, and Initiation subtests and better on the Attention and Construction subtests. This pattern was the same for the entire population as well as for the subgroup of subjects falling within the impaired range (i.e., 1.5 SDs below the mean of a geriatric population). Furthermore, performance was consistently lowest on the Conceptualization subtest. When individual items from the DRS were examined across the entire group, the group scored lowest on Digits Backward, followed by Sentence Recall, Supermarket Fluency, Verbal Conceptualization, and Orientation. With the exception of Digits Backward, these items belong to the three subtests in which our subject population performed the worst (Conceptualization, Memory, and Initiation). Digits Backward is grouped within the Attention subtest and is the only
6 1316 CANCER September 15, 2002 / Volume 95 / Number 6 item requiring complex attention within the subtest. In addition to these items, our subject population fell within the impaired range on Supermarket Fluency and Orientation. When patient impairments on these items are compared with the impairments found by Siegel et al., 15 they reflect the same general areas of dysfunction specified in that study: attention (Digits Backward), recent memory (Sentence Recall), and abstraction (Verbal Conceptualization). In general, this pattern of impairment suggests frontal-subcortical dysfunction, as the frontal lobe is highly involved in abstract reasoning, executive functioning, attention, and working memory. 16 Although the pattern of impairment was similar to the previous study, Siegel et al. 15 also found that 93% of their subjects fell within the impaired range of performance. In the current study, only 27% of the subject population met our criteria for impaired overall neuropsychological performance. However, the difficulty level between the tests used in the previous study (which were not fully specified) and the DRS may be significantly different. The DRS is a relatively easy test that is used often as a cognitive tool for screening older patients with dementia. This finding suggests that a critical level of assessment breadth and difficulty is necessary to capture subtle changes associated with LMD. Although a more thorough battery of tests (such as that used by Siegel et al. 15 ) would perhaps be more sensitive than a screening measure such as the DRS, the DRS may be more time-efficient and sufficient for capturing and tracking vital changes. This is an area for further exploration. To conclude, cognitive performance at the time of LMD diagnosis, as measured by total score on the DRS, predicted survival, whereas age and clinical status (KPS rating) did not. In particular, the Conceptualization subtest was the most sensitive to disease course. It was the only individual subtest to predict survival and it was the best measure of impairment across subjects. Conceptualization or reasoning ability is a cognitive process that is strongly dependent on frontal lobe functioning. These results support earlier findings of a frontal-subcortical pattern of dysfunction among LMD patients. 15 These conclusions hold implications for future studies, which might investigate the pattern of cognitive dysfunction throughout the course of LMD, both during and after treatment. In particular, the issue of whether cognitive performance, particularly reasoning ability, continues to predict disease course should be explored. If so, cognitive assessment may prove to be a valuable tool in making clinical and treatment decisions regarding these patients. REFERENCES 1. Chamberlain MC, Friedman HS. Leptomeningeal metastases. In: Levin VA, editor. Cancer in the nervous system. New York: Churchill Livingstone, 1996: New PZ. Central nervous system emergencies. In: Weiss GR, editor. Clinical oncology. Norwalk, CT: Appleton & Lange, 1993: List J, Moser RP, Steuer M, London WG, Blacklock JB, Grimm EA. Cytokine responses to intraventricular injection of interleukin-2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin-1-beta, interleukin-6, interferon, and soluble interleukin-2 receptor. Cancer Res. 1992;52: Meyers CA, Yung WKA. Delayed neurotoxicity of intraventricular interleukin-2: a case report. J Neurooncol. 1993;15: Meyers CA, Valentine AD, Wong FCL, Leeds NE. Reversible neurotoxicity of interleukin-2 and tumor necrosis factor: correlations of SPECT with neuropsychological testing. J Neuropsychiatry Clin Neurosci. 1994;6: Fathallah-Shaykh HM, Zimmerman C, Morgan H, Rushing E, Schold SC, Unwin DH. Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2. Cancer. 1996;77: Mattis S. Dementia Rating Scale. Odessa, FL: Psychological Resources, Inc., Hoffer SM, Piccinin AM, Hershey D. Analysis of structure and discriminative power of the Mattis Dementia Rating Scale. J Clin Psychiatry. 1996;52: Salmon DP, Yuen PFK, Heindel WC, Butters N, Thal LJ. Differentiation of Alzheimer s disease and Huntington s disease with the Dementia Rating Scale. Arch Neurol. 1989;46: Rosser AE, Hodges JR. The Dementia Rating Scale in Alzheimer s disease, Huntington s disease and progressive supranuclear palsy. J Neurol. 1994;241: Paulsen JS, Butters N, Sadek JR, et al. Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology. 1995;45: Medical Research Council Brain Tumour Working Party. Prognostic factors for high-grade malignant glioma: development of a prognostic index. J Neurooncol. 1990;9: Folstein MF, Folstein SE, McHugh PR. Mini-mental state : a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12: Meyers CA, Kudelka AP, Conrad CA, et al. Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res. 1997;3: Siegel T, Mildworf B, Stein D, Melamed E. Leptomeningeal metastases: reduction in regional cerebral blood flow and cognitive impairment. Ann Neurol. 1985;17: Lezak MD. Neuropsychological assessment, 3rd ed. New York: Oxford University Press, 1995.
Learn about Leptomeningeal Disease
Learn about Leptomeningeal Disease Information for patients and caregivers Princess Margaret Read this resource to learn: What is leptomeningeal disease What are the symptoms of leptomeningeal disease
More informationCopyright 2002 American Academy of Neurology. Volume 58(8) 23 April 2002 pp
Copyright 2002 American Academy of Neurology Volume 58(8) 23 April 2002 pp 1288-1290 Improved executive functioning following repetitive transcranial magnetic stimulation [Brief Communications] Moser,
More informationLeptomeningeal metastasis: management and guidelines. Emilie Le Rhun Lille, FR Zurich, CH
Leptomeningeal metastasis: management and guidelines Emilie Le Rhun Lille, FR Zurich, CH Definition of LM LM is defined as the spread of tumor cells within the leptomeninges and the subarachnoid space
More informationCHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there
More information21/05/2018. Today s webinar will answer. Presented by: Valorie O Keefe Consultant Psychologist
Today s webinar will answer. 1. What is the RBANS, and how is the updated version different than the original version? 2. What are the neurocognitive areas assessed by the RBANS and what scores are available?
More informationTable 2B: Summary of Select Screening and Initial Assessment Tools for Vascular Cognitive Impairment in Stroke Patients (Updated 2014)
Table 2B: Summary of Select Screening and Initial s for Vascular Cognitive Impairment in Stroke Patients (Updated 2014) Recommended First Line Screening and s Montreal Cognitive (MoCA) The MoCA is available
More informationCase Report Three Cases of Neoplastic Meningitis Initially Diagnosed with Infectious Meningitis in Emergency Department
Case Reports in Emergency Medicine Volume 2013, Article ID 561475, 4 pages http://dx.doi.org/10.1155/2013/561475 Case Report Three Cases of Neoplastic Meningitis Initially Diagnosed with Infectious Meningitis
More informationQuantitative analysis for a cube copying test
86 99 103 2010 Original Paper Quantitative analysis for a cube copying test Ichiro Shimoyama 1), Yumi Asano 2), Atsushi Murata 2) Naokatsu Saeki 3) and Ryohei Shimizu 4) Received September 29, 2009, Accepted
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationRecognition of Alzheimer s Disease: the 7 Minute Screen
265 Recognition of Alzheimer s Disease: the 7 Minute Screen Paul R. Solomon, PhD; William W. Pendlebury, MD Background and Objectives: Because Alzheimer s disease (AD) tends to be underdiagnosed, we developed
More informationLeptomeningeal Carcinomatosis: Risks, Detection, and Treatment. Goldie Kurtz, MD, FRCPC Department of Radiation Oncology University of Pennsylvania
Leptomeningeal Carcinomatosis: Risks, Detection, and Treatment Goldie Kurtz, MD, FRCPC Department of Radiation Oncology University of Pennsylvania May 13, 2016 Disclosures None to declare 2 Outline Epidemiology
More informationPRELIMINARY NORMS FOR YEAR OLDS ON THE MEMORY TEST FOR OLDER ADULTS (MTOA:S) ABSTRACT
The University of British Columbia PRELIMINARY NORMS FOR 85-99 YEAR OLDS ON THE MEMORY TEST FOR OLDER ADULTS (MTOA:S) Anita M. Hubley University of British Columbia Vancouver, BC, Canada Poster presented
More informationPage 1 of 5 DIAGNOSIS RISK STATUS TREATMENT WORKUP
Note: Consider Clinical Trials as treatment options f eligible patients. Signs and symptoms suggestive of leptomeningeal metastases Leptomeningeal Metastases WORKUP Physical exam with comprehensive neurologic
More informationConfusional state. Digit Span. Mini Mental State Examination MMSE. confusional state MRI
10 304 29 3 confusional state MRI 29 3 304 311 2009 Key Words memory test attention brain region causative disease subcortical dementia 1 Confusional state Digit Span 1 1 5 4 Mini Mental State Examination
More informationTHE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
More informationSemantic Processing Ability in Persian-Speaking Alzheimer s Patients
December 2016, Volume 14, Number 4 Semantic Processing Ability in Persian-Speaking Alzheimer s Patients CrossMark Omid Azad 1* 1. Department of Linguistics, Faculty of Persian Literature and Foreign Languages,
More informationKnowledge of Living and Nonliving Things in Dementia of the Alzheimer s Type
Original Article Knowledge of Living and Nonliving Things in Dementia of the Alzheimer s Type S Gopaljee Abstract This paper examines methodological issues concerning the measurement of semantic memory
More informationTable 7.2B: Summary of Select Screening Tools for Assessment of Vascular Cognitive Impairment in Stroke Patients
Table 7.2B: Summary of Select Screening Tools for Assessment of Vascular Cognitive Impairment in Stroke Patients Recommended First Line Screening and s Montreal Cognitive (MoCA) The MoCA is available for
More informationORIGINAL ARTICLE Neuroscience INTRODUCTION MATERIALS AND METHODS
ORIGINAL ARTICLE Neuroscience DOI: 10.46/jkms.2010.25.7.1071 J Korean Med Sci 2010; 25: 1071-1076 Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring
More informationNEUROPSYCHOMETRIC TESTS
NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract
More informationTest Assessment Description Ref. Global Deterioration Rating Scale Dementia severity Rating scale of dementia stages (2) (4) delayed recognition
Table S. Cognitive tests used in the Georgia Centenarian Study. Test Assessment Description Ref. Mini-Mental State Examination Global cognitive performance A brief screening of orientation, memory, executive
More informationNeurosurgery Review. Mudit Sharma, MD May 16 th, 2008
Neurosurgery Review Mudit Sharma, MD May 16 th, 2008 Dr. Mudit Sharma, Neurosurgeon Manassas, Fredericksburg, Virginia http://www.virginiaspinespecialists.com Phone: 1-855-SPINE FIX (774-6334) Fundamentals
More informationReferring to Part of the Dossier. Protocol No.: DEP1501 EudraCT/IND No.:
2. SYNOPSIS Name of Sponsor: Mundipharma Research Limited Name of Finished Product: epocyte Name of Active Ingredient: Cytarabine Liposome Injection INIVIUAL STUY TABLE Referring to Part of the ossier
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM BRAIN METASTASES CNS Site Group Brain Metastases Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationTreatment of AD with Stabilized Oral NADH: Preliminary Findings
MS # 200 000 128 Treatment of AD with Stabilized Oral NADH: Preliminary Findings G.G. Kay, PhD, V. N. Starbuck, PhD and S. L. Cohan, MD, PhD Department of Neurology, Georgetown University School of Medicine
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More informationPATIENTS WITH RECURRENT malignant gliomas,
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials By Eric T. Wong, Kenneth R. Hess, Mary Jo Gleason, Kurt A. Jaeckle, Athanassios P. Kyritsis, Michael
More informationBrain and Spine Tumors
Brain and Spine Tumors Andrew J. Fabiano, MD FAANS Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine Brain Tumors Brain Tumor Basics Types of Tumors Cases
More informationORIGINAL CONTRIBUTION. Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals
ORIGINAL CONTRIBUTION Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals Sid E. O Bryant, PhD; Joy D. Humphreys, MA; Glenn E. Smith, PhD; Robert J. Ivnik, PhD; Neill
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationBrain and Central Nervous System Cancers
Brain and Central Nervous System Cancers NICE guidance link: https://www.nice.org.uk/guidance/ta121 Clinical presentation of brain tumours History and Examination Consider immediate referral Management
More informationAGED SPECIFIC ASSESSMENT TOOLS. Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services
AGED SPECIFIC ASSESSMENT TOOLS Anna Ciotta Senior Clinical Neuropsychologist Peninsula Mental Health Services Issues in assessing the Elderly Association between biological, psychological, social and cultural
More informationMR Imaging of Leptomeningeal Metastases: Comparison of Three Sequences
AJNR Am J Neuroradiol 23:817 821, May 2002 MR Imaging of Leptomeningeal Metastases: Comparison of Three Sequences Sanjay K. Singh, Norman E. Leeds, and Lawrence E. Ginsberg BACKGROUND AND PURPOSE: Recent
More informationI n the past three decades various cognitive screening
700 PAPER The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia E F J Meulen, B Schmand, J P van Campen, S J de Koning, R W Ponds, P Scheltens, F R Verhey...
More informationWHI Memory Study (WHIMS) Investigator Data Release Data Preparation Guide April 2014
WHI Memory Study (WHIMS) Investigator Data Release Data Preparation Guide April 2014 1. Introduction This release consists of a single data set from the WHIMS Epidemiology of Cognitive Health Outcomes
More informationElderly Norms for the Hopkins Verbal Learning Test-Revised*
The Clinical Neuropsychologist -//-$., Vol., No., pp. - Swets & Zeitlinger Elderly Norms for the Hopkins Verbal Learning Test-Revised* Rodney D. Vanderploeg, John A. Schinka, Tatyana Jones, Brent J. Small,
More informationUDS version 3 Summary of major changes to UDS form packets
UDS version 3 Summary of major changes to UDS form packets from version 2 to VERSION 3 february 18 final Form A1: Subject demographics Updated question on principal referral source to add additional options
More informationChallenging Paediatric Brain Tumours. ASP Belfast March 2017 Dr Jane Pears Consultant Paediatric Oncologist, Dublin
Challenging Paediatric Brain Tumours ASP Belfast March 2017 Dr Jane Pears Consultant Paediatric Oncologist, Dublin Overview (i) Paediatric malignancy (ii) Central nervous system tumours (iii) Diffuse Intrinsic
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Cognitive impairment evaluated with Vascular Cognitive Impairment Harmonization Standards in a multicenter prospective stroke cohort in Korea Supplemental Methods Participants From
More informationNeurocognitive Assessment in Patients with Brain Metastases. Martin Klein VU University Medical Center Amsterdam, The Netherlands
Neurocognitive Assessment in Patients with Brain Metastases Martin Klein VU University Medical Center Amsterdam, The Netherlands Treatment Outcomes I Traditional/primary endpoints of efficacy:! Physician
More informationBrain Tumors. What is a brain tumor?
Scan for mobile link. Brain Tumors A brain tumor is a collection of abnormal cells that grows in or around the brain. It poses a risk to the healthy brain by either invading or destroying normal brain
More informationWhat are brain and spinal cord tumours? Contents
13 11 20 Information and support What are brain and spinal cord tumours? Contents The brain and spinal cord Brain function What is a brain or spinal cord tumour? What types of tumours are there? How common
More informationDifferentiation of semantic dementia and Alzheimer s disease using the Addenbrooke s Cognitive Examination (ACE)
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2008; 23: 370 375. Published online 4 September 2007 in Wiley InterScience (www.interscience.wiley.com).1887 Differentiation of semantic
More informationUnited Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline
United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline REV 3/24/09 The UCNS Geriatric Neurology examination was established to determine the level of competence
More informationThe Five-Point Test: Reliability, Validity and Normative Data for Children and Adults
The Five-Point Test: Reliability, Validity and Normative Data for Children and Adults Lara Tucha 1 *, Steffen Aschenbrenner 2, Janneke Koerts 1, Klaus W. Lange 3 1 Department of Clinical and Developmental
More informationAD Prevention Trials: An Industry Perspective
AD Prevention Trials: An Industry Perspective Robert A. Lasser, MD, MBA Global Development Lead, Product Development Group Medical Director, Neurodegenerative Disorders F. Hoffmann - La Roche Ltd Regulatory
More informationORIGINAL CONTRIBUTION. Cognitive Profiles of Autopsy-Confirmed Lewy Body Variant vs Pure Alzheimer Disease
ORIGINAL CONTRIBUTION Cognitive Profiles of Autopsy-Confirmed Lewy Body Variant vs Pure Alzheimer Disease Donald J. Connor, PhD; David P. Salmon, PhD; Teresa J. Sandy, BS; Douglas Galasko, MD; Lawrence
More informationLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic, 1 MR Migden, 2 AE Oro, 3 L Dirix, 4 K Lewis,
More informationContextual bias and inferencing in adults with right hemisphere brain damage It is widely accepted that damage to the right cerebral hemisphere (RHD)
Contextual bias and inferencing in adults with right hemisphere brain damage It is widely accepted that damage to the right cerebral hemisphere (RHD) can cause difficulty with discourse comprehension.
More information(7) VITAL SIGNS (8) LEVEL OF CONSCIOUSNESS (9) MENTAL STATUS (10) SPEECH (11) VISION (12) FUNDUS (PAPILLEDEMA)
Radiation Therapy Oncology Group Phase II CNS Lymphoma Follow-Up Form RTOG Study No. 1114 Case # Amended Data Yes INSTRUCTIONS: Submit this form as indicated in the protocol. All dates need to be recorded
More informationHydrocephalus 1/16/2015. Hydrocephalus. Functions of Cerebrospinal fluid (CSF) Flow of CSF
Hydrocephalus Hydrocephalus Ruth Arms, MSN, CNS-BC, SCRN Hydrocephalus is the buildup of fluid in the cavities (ventricles) deep within the brain. The excess fluid increases the size of the ventricles
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationOutcome and Prognosis of Metastatic Brain Tumour: A Study of 35 Cases
Bangladesh Journal of Neuroscience 2008; Vol. 24 (1) : 17-23 Outcome and Prognosis of Metastatic Brain Tumour: A Study of 35 Cases HARADHAN DEB NATH 1, KANAK KANTI BARUA 2, MOHAMMAD AFZAL HOSSAIN 3, MD
More informationAdult Brain and Spinal Cord Tumors
Adult Brain and Spinal Cord Tumors An adult central nervous system (CNS) tumor is a disease in which abnormal cells form in the tissues of the brain and or the spinal cord. Major Parts of the Brain Anatomy
More informationNON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
More informationHubley Depression Scale for Older Adults (HDS-OA): Reliability, Validity, and a Comparison to the Geriatric Depression Scale
The University of British Columbia Hubley Depression Scale for Older Adults (HDS-OA): Reliability, Validity, and a Comparison to the Geriatric Depression Scale Sherrie L. Myers & Anita M. Hubley University
More informationInformation Gathering Obtaining history is the most critical first step Patient-provided history may not be reliable Need info from relatives, friends
ASSESSING COMPETENCE Michael A Hill MD UNC Psychiatry 2008 Information Gathering Obtaining history is the most critical first step Patient-provided history may not be reliable Need info from relatives,
More informationBrain tissue and white matter lesion volume analysis in diabetes mellitus type 2
Brain tissue and white matter lesion volume analysis in diabetes mellitus type 2 C. Jongen J. van der Grond L.J. Kappelle G.J. Biessels M.A. Viergever J.P.W. Pluim On behalf of the Utrecht Diabetic Encephalopathy
More informationNON MALIGNANT BRAIN TUMOURS Facilitator. Ros Taylor Advanced Neurosurgical Nurse Practitioner Southmead Hospital Bristol
NON MALIGNANT BRAIN TUMOURS Facilitator Ros Taylor Advanced Neurosurgical Nurse Practitioner Southmead Hospital Bristol Neurosurgery What will be covered? Meningioma Vestibular schwannoma (acoustic neuroma)
More informationCNS TUMORS. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
CNS TUMORS D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) CNS TUMORS The annual incidence of intracranial tumors of the CNS ISmore than intraspinal tumors May be Primary or Secondary
More informationAmerican Journal of. Medical Case Reports. CAM5.2 Expression in Metastatic Tumours of CNS: A Diagnostic Tool
American Journal of American Journals of Medical Case Reports http://ivyunion.org/index.php/ajmcr/index Medical Case Reports Mathur SK et al. American Journal of Medical Case Reports 2014, 2:1-8 Vol 2,
More informationMINI-MENTAL STATE EXA MINATION (M MSE)
MINI-MENTAL STATE EXA MINATION (M MSE) M axim u m Score Score 5 5 Orientation What is the (day of week) (day of month) (month) (year) (season)? Where are we: (state) (county) (town) (facility) (floor)?
More informationUse a diagnostic neuropsychology HOW TO DO IT PRACTICAL NEUROLOGY
170 PRACTICAL NEUROLOGY HOW TO DO IT Pract Neurol: first published as 10.1046/j.1474-7766.2003.08148.x on 1 June 2003. Downloaded from http://pn.bmj.com/ Use a diagnostic neuropsychology on 16 October
More informationO Connor 1. Appendix e-1
O Connor 1 Appendix e-1 Neuropsychiatric assessment The Cambridge Behavioural Inventory Revised (CBI-R) 1, 2 is a proxy behavioural questionnaire that has been extensively used in studies involving FTD
More informationCHAPTER 2 CRITERION VALIDITY OF AN ATTENTION- DEFICIT/HYPERACTIVITY DISORDER (ADHD) SCREENING LIST FOR SCREENING ADHD IN OLDER ADULTS AGED YEARS
CHAPTER 2 CRITERION VALIDITY OF AN ATTENTION- DEFICIT/HYPERACTIVITY DISORDER (ADHD) SCREENING LIST FOR SCREENING ADHD IN OLDER ADULTS AGED 60 94 YEARS AM. J. GERIATR. PSYCHIATRY. 2013;21(7):631 635 DOI:
More informationCLINICAL NEUROPSYCHOLOGY Course Syllabus, Spring 2018 Columbia University
CLINICAL NEUROPSYCHOLOGY Course Syllabus, Spring 2018 Columbia University Instructor: E mett McCaskill, PhD Office: 356 SchExt, Columbia University; 415-O Milbank Hall, Barnard College Email: e.mccaskill@columbia.edu
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a preprint version which may differ from the publisher's version. For additional information about this
More informationErin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
More informationPresented By: Yip, C.K., OT, PhD. School of Medical and Health Sciences, Tung Wah College
Presented By: Yip, C.K., OT, PhD. School of Medical and Health Sciences, Tung Wah College Background of problem in assessment for elderly Key feature of CCAS Structural Framework of CCAS Methodology Result
More informationUpdate on Pediatric Brain Tumors
Update on Pediatric Brain Tumors David I. Sandberg, M.D. Director of Pediatric Neurosurgery & Associate Professor Dr. Marnie Rose Professorship in Pediatric Neurosurgery Pre-talk Questions for Audience
More informationThe Repeatable Battery for the Assessment of Neuropsychological Status Effort Scale
Archives of Clinical Neuropsychology 27 (2012) 190 195 The Repeatable Battery for the Assessment of Neuropsychological Status Effort Scale Julia Novitski 1,2, Shelly Steele 2, Stella Karantzoulis 3, Christopher
More informationRapidly-administered short forms of the Wechsler Adult Intelligence Scale 3rd edition
Archives of Clinical Neuropsychology 22 (2007) 917 924 Abstract Rapidly-administered short forms of the Wechsler Adult Intelligence Scale 3rd edition Alison J. Donnell a, Neil Pliskin a, James Holdnack
More informationTHE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME
PERNECZKY 15/06/06 14:35 Page 1 THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME R. PERNECZKY, A. KURZ Department of Psychiatry and Psychotherapy, Technical University of Munich, Germany. Correspondence
More informationHopkins Verbal Learning Test Revised: Norms for Elderly African Americans
The Clinical Neuropsychologist 1385-4046/02/1603-356$16.00 2002, Vol. 16, No. 3, pp. 356 372 # Swets & Zeitlinger Hopkins Verbal Learning Test Revised: Norms for Elderly African Americans Melissa A. Friedman
More informationNeuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
More informationMild cognitive impairment A view on grey areas of a grey area diagnosis
Mild cognitive impairment A view on grey areas of a grey area diagnosis Dr Sergi Costafreda Senior Lecturer Division of Psychiatry, UCL Islington Memory Service, C&I NHS FT s.costafreda@ucl.ac.uk London
More informationTrail making test A 2,3. Memory Logical memory Story A delayed recall 4,5. Rey auditory verbal learning test (RAVLT) 2,6
NEUROLOGY/2016/790584 Table e-1: Neuropsychological test battery Cognitive domain Test Attention/processing speed Digit symbol-coding 1 Trail making test A 2,3 Memory Logical memory Story A delayed recall
More informationRunning head: CPPS REVIEW 1
Running head: CPPS REVIEW 1 Please use the following citation when referencing this work: McGill, R. J. (2013). Test review: Children s Psychological Processing Scale (CPPS). Journal of Psychoeducational
More informationProcess of a neuropsychological assessment
Test selection Process of a neuropsychological assessment Gather information Review of information provided by referrer and if possible review of medical records Interview with client and his/her relative
More informationThe Relationship Between Age and Cognitive Function in HIV-Infected Men
The Relationship Between Age and Cognitive Function in HIV-Infected en Emily C. Kissel Nicole D. Pukay-artin, B.A. Robert A. Bornstein, Ph.D. Several studies have identified increased age as a risk factor
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationClinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
More informationPrimary Central Nervous System Lymphoma with Lateral Ventricle Involvement
The Open Medical Imaging Journal, 2012, 6, 103-107 103 Open Access Primary Central Nervous System Lymphoma with Lateral Ventricle Involvement Yumi Oie 1,*, Kazuhiro Murayama 1, Shinya Nagahisa 2, Masato
More informationDOES IMPAIRED EXECUTIVE FUNCTIONING DIFFERENTIALLY IMPACT VERBAL MEMORY MEASURES IN OLDER ADULTS WITH SUSPECTED DEMENTIA?
The Clinical Neuropsychologist, 20: 230 242, 2006 Copyright # Taylor and Francis Group, LLC ISSN: 1385-4046 print=1744-4144 online DOI: 10.1080/13854040590947461 DOES IMPAIRED EXECUTIVE FUNCTIONING DIFFERENTIALLY
More informationmini- Kingston Standardized Cognitive Assessment (REV)
mini- Kingston Standardized Cognitive Assessment (REV) (mini-kscar) Instruction and Scoring Manual The Kingston Scales and Manuals can be downloaded free of charge from: www.kingstonscales.ca email: kscales@queensu.ca
More informationLocalizing lesion locations to predict extent of aphasia recovery. Abstract
Localizing lesion locations to predict extent of aphasia recovery Abstract Extensive research has related specific lesion locations to language impairment in aphasia. However, far less work has focused
More informationService Related Project. Kimberley Keegan
AN EVALUATION OF ADDENBROOKE S COGNITIVE EXAMINATION III (ACE-III) SCORES, NEUROPSYCHOLOGICAL ASSESSMENT SCORES, AND DIAGNOSIS OUTCOME WITHIN A MEMORY SERVICE. Service Related Project Kimberley Keegan
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationA semantic verbal fluency test for English- and Spanish-speaking older Mexican-Americans
Archives of Clinical Neuropsychology 20 (2005) 199 208 A semantic verbal fluency test for English- and Spanish-speaking older Mexican-Americans Hector M. González a,, Dan Mungas b, Mary N. Haan a a University
More informationDosimetry, see MAGIC; Polymer gel dosimetry. Fiducial tracking, see CyberKnife radiosurgery
Subject Index Acoustic neuroma, neurofibromatosis type 2 complications 103, 105 hearing outcomes 103, 105 outcome measures 101 patient selection 105 study design 101 tumor control 101 105 treatment options
More informationORIGINAL CONTRIBUTION. Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment
ORIGINAL CONTRIBUTION Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment David F. Tang-Wai, MDCM; David S. Knopman, MD; Yonas E. Geda, MD;
More informationDementia. Assessing Brain Damage. Mental Status Examination
Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological
More informationMALIGNANT GLIOMAS: TREATMENT AND CHALLENGES
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN
More informationliposomal cytarabine suspension (DepoCyte ) is not recommended for use within NHS Scotland for the intrathecal treatment of lymphomatous meningitis.
Scottish Medicines Consortium Re-Submission liposomal cytarabine 50mg suspension for injection (DepoCyte) No. (164/05) Napp Pharmaceuticals 6 July 2007 The Scottish Medicines Consortium (SMC) has completed
More informationCognitive Screening in Risk Assessment. Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University.
Cognitive Screening in Risk Assessment Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University Outline of Talk Definition of Dementia and MCI Incidence and Prevalence
More informationAppraisal of carmustine. implants and temozolomide. for newly diagnosed high. Brain and Spine Foundation
Appraisal of carmustine implants and temozolomide for newly diagnosed high grade glioma Brain and Spine Foundation June 2005 Submission to the National Institute for Health and Clinical Excellence Brain
More informationMalignant melanoma and the central nervous system A guide for classification based on the clinical findings
Journal ofneurology, Neurosurgery, and Psychiatry, 1976, 39, 526-530 Malignant melanoma and the central nervous system A guide for classification based on the clinical findings R. D. HAYWARD From the Department
More informationMetastatic Brain Tumors
Metastatic Brain Tumors F O C U S I N G O N T U M O R S American Brain Tumor Association A Word About ABTA Founded in 1973, the American Brain Tumor Association was the first national, nonprofit organization
More informationM P---- Ph.D. Clinical Psychologist / Neuropsychologist
M------- P---- Ph.D. Clinical Psychologist / Neuropsychologist NEUROPSYCHOLOGICAL EVALUATION Name: Date of Birth: Date of Evaluation: 05-28-2015 Tests Administered: Wechsler Adult Intelligence Scale Fourth
More informationRemembering the Past to Imagine the Future: A Cognitive Neuroscience Perspective
MILITARY PSYCHOLOGY, 21:(Suppl. 1)S108 S112, 2009 Copyright Taylor & Francis Group, LLC ISSN: 0899-5605 print / 1532-7876 online DOI: 10.1080/08995600802554748 Remembering the Past to Imagine the Future:
More information